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ABSTRACT: The inﬂammatory response represents a ﬁrst
line of defense against invading pathogens and is important to
human health. Chronic inﬂammation contributes to the
etiology of multiple diseases, especially those associated with
aging, such as cancer and cardiovascular disease. The chemistry
of the inﬂammatory response is complex and involves the
generation of highly reactive oxidants and electrophiles designed to kill the pathogen as well as the release of small molecule and
protein mediators of intercellular signaling, chemotaxis, vasoconstriction, and wound-healing. Oxidation of unsaturated fatty
acidseither nonenzymatic or enzymaticcontributes to the inﬂammatory response and associated cellular pathologies. The
current perspective summarizes our research on unsaturated fatty acid oxidation in the context of inﬂammation and cancer. In
addition to understanding the consequences of DNA and protein modiﬁcation by lipid electrophiles, our research has focused on
the development of molecularly targeted agents to image and treat cancer.
I
nﬂammation is a systemic response to pathogen challenge
and injury. It is characterized by the inﬂux of inﬂammatory
cells (e.g., macrophages and neutrophils), induction of vaso-
constriction, edema (swelling), erythema (redness), and
sensitivity to pain.
1 The logic of inﬂammation is to defend
against the invading pathogen by conducting chemical warfare
while limiting damage to the region of the initial infection.
Ultimately, inﬂammatory lesions resolve, and local wounds heal.
Acute inﬂammation is a critical element of host defense, and
individuals with genetic mutations that disable the inﬂamma-
tory response are at elevated risk of infection.
2 Although acute
inﬂammation is beneﬁcial to the organism (albeit perhaps
painful and annoying), chronic inﬂammation contributes to the
etiology of many diseases. The list is too long to tabulate but
includes cancer, cardiovascular disease, and diabetes. There are
many mediators generated during an inﬂammatory response.
Some contribute to the toxicological events that kill the
invading pathogen, whereas others recruit additional inﬂam-
matory cells to the site of the lesion, induce vasoconstriction, or
promote resolution and wound healing. Oxidized lipids,
particularly those derived from polyunsaturated fatty acids,
contribute to all of these events.
3 Our group studies the
chemical events that contribute to inﬂammation, especially as
they relate to cancer. This perspective will highlight some of the
key chemical reactions associated with inﬂammation and cancer
that may be mediated by oxygenated metabolites of poly-
unsaturated fatty acids.
Reactive Species Generated During Inﬂammation.
During the inﬂammatory response, professional killer cells such
as macrophages generate a panoply of highly reactive oxidants
as part of the chemical warfare waged on an invading pathogen
(Figure 1).
4,5 All of these oxidants derive from the production
of two free radical speciesthe superoxide anion radical (O2
−)
and nitric oxide (￿NO). Activation of macrophages or neutro-
phils by particulate or soluble stimuli triggers a burst of O2
consumption catalyzed by the cell surface protein, NADPH
oxidase, which transfers an electron from NADPH to oxygen
to form O2
−.
6 There are a number of NADPH oxidases in
humans, but the enzyme in neutrophils and macrophages
catalyzes a particularly robust reduction of O2.
7 Concomitant
with O2 reduction, arginine is oxidized to ￿NO by nitric oxide
synthase (NOS).
8 There are three NOS’s in human tissue, but
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Figure 1. Production of reactive species by activated macrophages and
neutrophils during the inﬂammatory response. Reproduced with
permission from ref 5. Copyright 2011. Wiley. The artist is Jeﬀ Dixon.
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particular interest with respect to inﬂammation.
9
Coupling of ￿NO to O2
− occurs at a near diﬀusion-controlled
rate to form peroxynitrite (NOOO−).
10 NOOO− is a strong
nucleophile, and its protonated form, peroxynitrous acid
(NOOOH), is an extremely strong oxidant.
11 It is capable of
directly reacting with organic moieties or undergoing homolysis
to nitrogen dioxide (NO2
￿) and hydroxyl radical (HO￿).
12
NOOO− is also capable of coupling to carbon dioxide to form
peroxynitrosocarbonate (NOOOCO2
−).
13 Homolysis of
NOOOCO2
− generates the carbonate radical (￿OCO2
−) and
NO2
￿.
14 One-electron oxidation of an organic donor (e.g.,
amino acids or nucleic acids) by the carbonate radical generates
a new product radical that can couple to NO2
￿, resulting in
nitration.
15 Nitrated proteins have been detected at sites of
chronic inﬂammation.
16
O2
− is not a strong oxidant and, in fact, acts as a reductant of
Fe3+ to form Fe2+.
17 O2
− dismutates to H2O2, which is also
a relatively weak oxidant (Figure 1).
18 However, reduction of
H2O2 by Fe2+ results in the production of HO￿, which is an
extremely strong oxidant.
19 In inﬂammatory cells, H2O2 is also
a substrate for peroxidases that oxidize halogens to form hypo-
halous acids. Macrophages and neutrophils primarily make
HOCl, whereas eosinophils produce HOBr.
20,21 A fraction of
HOCl reacts with Cl− to form Cl2.
22
Table 1 summarizes the properties of the ultimate reactive
species generated during the inﬂammatory response. Most of
them are oxidants; in fact, HO￿ and ￿OCO2
− are among the
most potent oxidants known and are capable of reacting with
most biomolecules. N2O3 is the only “pure electrophile” in
Table 1, although both HOCl and HOBr are capable of acting
as oxidants or electrophiles (via halide transfer). A rough
indication of the cellular targets is provided in Table 1, but the
breadth of actual targets is far too extensive to summarize in a
short format. This array of reactive oxidants, nitrating agents,
and halogenating agents is key to killing invading pathogens,
but the collateral damage of this carpet-bombing approach can
be substantial.
Most cellular constituents can be oxidized, nitrated, or
chlorinated by the species in Figure 1, but membrane con-
stituents are particularly sensitive to reaction. This is due to the
ubiquity of membranes throughout cells combined with the
presence of monounsaturated or polyunsaturated fatty acids at
the sn-2 position of every glycerophospholipid molecule of
every membrane.
28 Unsaturated fatty acid groups are prone to
oxidation because of the presence of allylic H atoms. The bis-
allylic H atoms in polyunsaturated fatty acids are even more
sensitive to oxidation, and the reactivity increases with the
number of double bonds.
29 The quantitatively and biologically
most signiﬁcant polyunsaturated fatty acids are linoleic acid
(18:2) and arachidonic acid (20:4) (Figure 2). Removal of the
allylic H atom produces a carbon-centered radical that couples
to O2 to form a peroxyl radical. Peroxyl radicals are reasonably
strong oxidants and can oxidize neighboring polyunsaturated
fatty acid residues in phospholipid membranes. These radical
cascades can exhibit long chain lengths. For example, it is
estimated that some 200 molecules of 20:4 can be oxidized
per initial oxidation event.
30 Vitamin E serves as the principal
membrane-bound antioxidant that interrupts these chains,
terminating autoxidation and protecting membranes from
further degradation.
31 The vitamin E phenoxyl radical produced
by reduction of lipid peroxyl radicals decays to quinone or
epoxide products that prevent propagation of lipid oxidation.
32
■ DNA DAMAGE FROM LIPID ELECTROPHILES
The fatty acid hydroperoxides generated initially during the
reaction of polyunsaturated fatty acids with oxidants are subject
to chemical breakdown to a variety of products (Figure 3).
33
These include enals, enones, and epoxy alcoholslipid electro-
philes that react with cellular nucleophiles. The discovery that
one of these aldehydes, malondialdehyde (MDA), is mutagenic
and carcinogenic stimulated our interest in the possibility that
Table 1. Properties of Reactive Species Generated During the Inﬂammatory Response
species reactivity reaction cellular target(s)
OH￿ oxidant OH￿ +H + +e − → H2O most protein functional groups
Eo′ = +2.31 V (pH 7.0, NHE)
23 addition to alkenes
CO3
￿‑ oxidant CO3
￿− +H + +e − → HCO3
− most protein functional groups
Eo′ = +1.78 V (pH 7.0, NHE)
24 nucleic acids (guanine)
HOCl oxidant 2HClO + 2H+ +2 e − → Cl2 +2 H 2O thiols, amines
Eo′ = +1.63 V (pH 7.0, NHE)
25 nucleic acids (guanine)
alkenes
HOBr oxidant 2HBrO + 2H+ +2 e − → Br2 +2 H 2O thiols, amines
Eo′ = +1.59 V (pH 7.0, NHE)
25 nucleic acids (guanine)
alkenes
ONOO− oxidant ONOO− +2 H + +e − → NO2
￿ +H 2O sulfhydryl groups
Eo′ = +1.4 V (pH 7.0, NHE)
26 metalloproteins
NO2
￿ oxidant NO2
￿ +e − → NO2
− sulfhydryl groups, phenols
Eo′ = +1.04 V (pH 7.0, NHE)
27 addition to alkenes
N2O3 electrophile Nuc-H + N2O3 → Nuc-NO + NO2
− +H + thiols, amines
Figure 2. Polyunsaturated fatty acids and lipid peroxidation.
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ation of MDA could serve as a link between chronic inﬂam-
mation and the generation of DNA damage leading to genetic
mutation.
34,35 At the time, most of the attention in the
carcinogenesis community was focused on environmental in-
sults to DNA as the principal causative factor for cancer etiology.
Thus, the possibility of “self-inﬂicted toxicity” was novel and
presented interesting problems in chemical toxicology.
DNA Adducts. Our initial eﬀorts in this area focused on the
identiﬁcation of chemical adducts formed by the reaction of
MDA with DNA. This turned out to be much more com-
plicated than initially anticipated because MDA, or more
correctly β-hydroxyacrolein (Figure 4), is as good a nucleophile
as it is an electrophile and undergoes oligomerization under
conditions of its chemical generation. Thus, adducts to de-
oxyguanosine, deoxyadenosine, and deoxycytidine were formed
by reaction of MDA as well as by reaction with dimers and
trimers of MDA (Figure 4).
36−40 The structures of these
interesting adducts suggested that they should block DNA
replication or induce mutations by virtue of the fact that they
either completely disrupted or attached sizable organic func-
tionality to exocyclic amino groups in the Watson−Crick base-
pairing region of the adducted base.
Mutagenic Consequences of DNA Damage. The
diversity of adducts illustrated in Figure 4 rendered it diﬃcult
to directly relate adduct structure to particular mutations in-
duced by MDA treatment of an intact cell. Direct reaction of
MDA with plasmid DNA followed by replication in E. coli
demonstrated that mutations were induced at dG, dA, and dC
residues (primarily dG→dT transversions, dA→dG transitions,
and dC→dT transitions, respectively) (Figure 5).
41
This mutation spectrum was consistent with the chemistry of
DNA modiﬁcation if one made the assumption that mutations
at particular nucleosides resulted from the replication of an
adduct formed at that nucleoside. To test this, a more direct
method for relating adduct structure to mutation was em-
ployed. Site-speciﬁc mutagenesis is a technique in which a
chemical adduct of known structure is built into a single
position of a DNA molecule that is capable of being replicated
in a bacterial or mammalian cell. Since the vectors typically
used contain 5000−7000 nucleotides, this would appear to be a
formidable synthetic challenge. In fact, a combination of or-
ganic synthesis and genetic engineering makes singly adducted
vector construction relatively straightforward (Figure 6).
The principal challenge is the chemistry of oligonucleotide
synthesis rather than engineering the vector. Many DNA
adducts are not stable to the conditions of oligonucleotide
synthesis or deprotection. We adopted two approaches to
incorporate the MDA adduct, M1dG, into oligonucleotides for
site-speciﬁc mutagenesis. The ﬁrst involved a total synthesis
in which enzymatically prepared M1dG was converted to a
dimethoxytrityl phosphoramidite derivative for incorporation
by an oligonucleotide synthesizer.
42,43 The base lability of
M1dG precluded ammonia deprotection, so acetoxymethyben-
zoyl protecting groups and sodium carbonate deprotection
were employed (Figure 7).
43
Analysis of the product oligonucleotide revealed that the
pyrimidopurinone ring-opened hydrolytically above pH 10
to an oxopropenal derivative that rapidly cyclized to the
Figure 3. Breakdown of PUFAs to electrophiles.
Figure 4. Oligomerization of MDA and the formation of DNA adducts.
Figure 5. Random mutagenesis experiments with MDA. A single-
stranded M13 bacteriophage genome was reacted with MDA to
randomly introduce adducts. The adducted vector was replicated in
E. coli. and mutations were identiﬁed by a combination of screening for
mutants and DNA sequencing.
41
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43 This
allowed for the introduction of the pyrimidopurinone in a site-
speciﬁc manner, albeit by a methodology that required the
synthesis of nonstandard protected nucleotide monomers. This
approach allowed us to conduct our initial biological experi-
ments, but subsequently we adopted a postoligomerization
strategy described by Rizzo and colleagues following up on the
initial reports of Johnson and Harris.
44 This postoligomeriza-
tion methodology, illustrated in Figure 8, allows for adduct
incorporation into already constructed oligonucleotides con-
taining electrophilic nucleotides at the desired adduct position.
This approach is not only more ﬂexible but allows in-
corporation of the other MDA adducts, OPdA and OPdC,
which are too unstable to sodium carbonate deprotection to
allow introduction by the total synthesis route. Vectors con-
taining the M1dG adduct were replicated in Escherichia coli
or mammalian cells and gave comparable results.
45,46 Fol-
lowing mutant selection and DNA sequencing, it was found
that replication of M1dG resulted in transversions to dT and
transitions to dA at approximately equal frequencies. The total
mutation frequency was approximately 2% of all the replication
events in either E. coli or mammalian cells. Although it seems
puzzling that an adduct that blocks the Watson Crick base-
pairing region would not have higher mutagenicity, it is
important to note that a mutation frequency of 2% is some ﬁve-
to-8 orders of magnitude higher than the mutation frequency
observed when unmodiﬁed DNA molecules are replicated.
Part of the reason for the “low” mutagenicity of M1dG was
revealed through studies of its conformation in duplex oligo-
nucleotides.
47 When single-stranded oligos containing M1dG
are hybridized to complementary oligonucleotides containing
dC opposite the lesion, M1dG rapidly ring-opens to an oxo-
propenyl derivative (Figure 9). The oxopropenyl group rotates
out of the Watson−Crick base-pairing region and into the
minor groove of the duplex.
47 Hydrogen bonding between the
adducted dG and the complementary dC is detected by NMR
spectroscopy.
48 When the duplex is thermally melted, the oxo-
propenyl group rapidly cyclizes to the pyrimidopurinone. Both
the initial ring-opening and the subsequent ring-closing are
catalyzed by DNA. This represents the ﬁrst discovery of a
DNA-catalyzed transformation of one DNA adduct into
another. Interestingly, when single-stranded oligonucleotides
containing M1dG are hybridized to complementary strands
containing a dT opposite the lesion, no ring-opening is
observed.
47 Therefore, duplex vectors containing M1dG oppo-
site dC or dT residues were constructed and replicated in
parallel. The ring-closed adduct was ﬁve times more mutagenic
than the ring-opened adduct.
45 This probably represents an
underestimate of the true diﬀerential in mutagenic potency
because the position of the equilibrium between M1dG and
OPdG in vivo cannot be determined. Nevertheless, in vitro
experiments in which adducted template-primers containing
either M1dG or OPdG were replicated by model DNA poly-
merases conﬁrmed the greater ability of the ring-closed adduct
to block replication and induce mutations.
48
The chemical biology of a number of adducts derived from
the reaction of lipid electrophiles other than MDA with DNA
has now been evaluated in several laboratories. The structures
and mutational outcomes of replication of these adducts are
summarized in Figure 10.
49 Since the bifunctional lipid electro-
philes form exocyclic adducts in the Watson−Crick base-pairing
region, it is not surprising that all of them exhibit some degree
of mutagenicity. Of particular interest, however, is heptanone−
ethenodeoxycytidine, a product of reaction of 4-oxononenal
with dC. This adduct is highly mutagenic, exhibiting nearly a
70% total mutation frequency when replicated in E. coli.
50
Repair of Exocyclic Adducts. The high mutagenicity of
the DNA adducts derived from lipid electrophiles suggests
repair is an important component of the cellular response to
DNA damage. Our investigations in vivo and in vitro revealed
that M1dG and related exocyclic adducts are eﬃcient sub-
strates for nucleotide-excision repair in which oligonucleotides
are excised and degraded to the level of deoxynucleosides
(Figure 11).
45,51
Figure 6. Construction of vectors containing a single deﬁned DNA
adduct.
Figure 7. Total synthesis of M1dG-containing oligonucleotides using AMB protecting groups.
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depicted in Figure 10. Interestingly, εdA is a relatively eﬃcient
substrate for a base-excision repair enzyme, alkyladenineglycosylase,
which removes the adducted base and replaces it following excision
of the deoxyribosyl unit.
52 εdA is also substrate for an oxygenase,
AlkB, that oxidizes the etheno ring to a vicinal diol, which
decomposes to glyoxal with regeneration of dA (Figure 12).
53 Thus
exocyclic adducts can be removed by nucleotide-excision repair,
base-excision repair, or direct repair of damaged DNA but the
extent to which each pathway participates depends on the adduct.
Figure 8. Synthesis of M1dG-containing oligonucleotides using a postoligomerization strategy.
Figure 9. Ring opening and closing of M1dG in duplex DNA. When a
dC residue is placed opposite M1dG, it opens quantitatively. No ring-
opening is observed with dT is placed opposite M1dG.
Figure 10. Summary of mutations induced in bacteria or mammalian cells by diﬀerent exocyclic adducts. The origin of the adduct is indicated.
Figure 11. General scheme of nucleotide-excision repair of M1dG
adducts. Incisions made on the 5′ and 3′ side of the adduct remove the
adduct-containing single-stranded oligonucleotide.
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lipid electrophile-dependent DNA damage occurs in healthy or
disease-bearing humans is a subject of great interest. Several
laboratories including our own have shown that exocyclic
adducts derived from endogenous electrophiles are con-
stituents of genomic DNA of healthy human beings as well
as rodents.
54−60 Although early analytical methods utilized gas
chromatography−mass spectrometry of volatile derivatives,
contemporary methods utilize liquid chromatography−mass
spectrometry of either the parental adduct or a stable conjugate
of it. These studies indicate that exocyclic adducts derived from
endogenous electrophiles are present at levels of approximately
1 adduct in 108−107 nucleotides or approximately 30−300
adducts per mammalian cell. Dedon and colleagues have
proﬁled a series of adducts derived from direct oxidation of
DNA, alkylation of DNA, and lipid electrophile damage to
DNA and found that under conditions of oxidative stress, lipid
electrophile adducts increase to a greater extent than the other
adducts.
61 This illustrates the potential for lipid electrophile−
DNA damage to play a role in human cancer.
More recently, our laboratory has developed methods to
quantify M1dG in urine and feces, providing a noninvasive way
for evaluating DNA damage in population-based studies.
62
These methods utilize immunoaﬃnity chromatography with
antibodies raised against the adduct to enrich it prior to liquid
chromatography−mass spectrometry. Preliminary studies illus-
trate that M1dG is present in human urine at levels of approxi-
mately 12 fmol/kg/day.
63 The level of M1dG in human urine is
much lower than that of the DNA oxidation product, 8-oxo-dG.
64
The low level of M1dG led us to explore the possibility that
it is metabolized following excision from DNA analogous
to other foreign compounds to which humans are exposed. In
fact, injection of M1dG into rodents in amounts from 8 mg/kg
body weight to 6 pg/kg leads to the production of a single
oxidative metabolite, 6-oxo-M1dG.
65−67 Experiments in rodents
indicate that M1dG is preferentially excreted in urine whereas
6-oxo-M1dG is preferentially excreted in feces (Figure 13).
67
Very recently, we have developed an immunoaﬃnity and
liquid chromatography−mass spectrometry-based method for
quantifying 6-oxo-M1dG in urine and feces.
68 Using this
method, we ﬁnd that 6-oxo-M1dG is present in feces of all the
rats that we evaluated at levels of 350−1893 fmol/kg/day.
6-Oxo-M1dG was detected in the urine of only one rat. By
contrast, M1dG was not detected in any of the animals’ urine or
feces. This indicates that 6-oxo-M1dG, produced by oxidation
of M1dG, is generated basally in rodents and preferentially
excreted in feces.
The potential metabolic fate of other exocyclic adducts has
not been proﬁled in a comprehensive fashion. However, we
Figure 12. Repair of εdA by glycosylase-catalyzed base excision repair (BER) and by AlkB-catalyzed oxidation.
Figure 13. Repair, metabolism, and excretion of M1dG and its metabolites in urine and bile (then excreted in feces).
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the chemistry is summarized in Figure 14.
69
■ LIPID ELECTROPHILE MODIFICATION OF PROTEIN
AND ITS RELATION TO THE RESULTING CELLULAR
RESPONSES
Lipid electrophile modiﬁcation of DNA is biologically im-
portant because of the genetic consequences of aberrant DNA
replication. However, there are other nucleophiles in cells that
are potentially as important, or more important, than DNA as
targets for electrophile modiﬁcation. Protein molecules appear
to be quantitatively more signiﬁcant targets for electrophile
modiﬁcation than DNA, and modiﬁcation of proteins alters
their function in a positive or negative way. Our interest in lipid
electrophile modiﬁcation of protein grew out of a comparison
of the eﬀects of bifunctional electrophiles on cell cycle pro-
gression and toxicity. We found that both MDA and 4-hydroxy-
2-nonenal (HNE) induce cell cycle arrest, but only HNE
induced toxicity to a colon cancer and a lung cancer cell
line.
70,71 In an attempt to understand the mechanism of the
induction of toxicity, we examined the eﬀects of HNE on
transcription factors known to play a role in cell replication or
resistance to cell death. Through these experiments, we found
that HNE inhibited transcription via the NFκB pathway, which
plays a role in protecting cells from toxic challenges.
72 Detailed
analysis of the impact of HNE on NFκB signaling revealed that
it covalently modiﬁes and inhibits the action of IκB kinase, the
protein kinase responsible for release of the NFκB transcription
factor from an inactive cytosolic complex.
72 HNE modiﬁcation
of IκB kinase inhibits the transcription of NFκB-dependent
genes that play a role in cell survival. Through this experience,
we developed an appreciation for the chemical complexity of
protein modiﬁcation by lipid electrophiles and the cellular
responses that they induce.
Protein Modiﬁcation by Lipid Electrophiles. We
decided to undertake a global analysis of protein modiﬁcation
and cellular response by lipid electrophiles to provide a com-
prehensive overview of their impact on cell signaling. It was
hoped that this overview would help prioritize protein targets
and cellular responses for further study. The complexity of
protein modiﬁcation as opposed to DNA modiﬁcation pro-
mpted us to choose a single lipid electrophile, HNE, as a model
and to pursue the acquisition of a complete inventory of
proteins modiﬁed by this molecule. The chemistry of
protein modiﬁcation by HNE is summarized in Figure 15.
The principal adducts are Michael addition products to cysteine,
histidine, and lysine with a small percentage of lysine imino
adducts.
73−75 The latter adducts undergo slow transformation
to pyrroles, and there is some evidence for chemical cross-
linking of the initial adducts.
The multiplicity of amino acids modiﬁed and the structures
of the adducts formed suggested that the method used to
inventory modiﬁed proteins needed to be independent of the
structure of the chemical adduct. We chose to use click
chemistry to perform this analysis. Alkynyl or azido derivatives
of HNE were synthesized and shown to be comparable to HNE
with regard to chemical reactivity with model peptides and
toxicity as well as gene expression induction.
77 This suggested
that these probes were excellent models for the parent
molecule. Using the protocol outlined in Figure 16, we were
able to modify cellular proteins with alkynyl or azido HNE,
then label them posthoc using an azido or alkynyl trap linked to
biotin. Use of a copper-catalyzed click reaction provided eﬃ-
cient trapping of protein molecules bearing an alkynyl or azido
tag. Biotinylated proteins were enriched by binding to
streptavidin-coated beads followed by washing of nonspeciﬁ-
cally adsorbed proteins and elution of the biotinylated proteins
by disrupting the biotin-streptavidin complexes.
77 An important
adaptation of this methodology from the Porter laboratory was
the incorporation of a photocleavable linker in the biotin tag.
78
Figure 14. Summary of products of metabolism of exocyclic DNA
adducts. The ﬁnal products are indicated in red. Reproduced from ref
69. 2009. American Chemical Society.
Figure 15. Products of amino acid adduction by HNE. Reproduced
from ref 76. 2010. American Chemical Society.
Figure 16. Click chemistry to enrich alkynyl-HNE-adducted proteins.
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adducted proteins by irradiation of the streptavidin beads. This
dramatically reduces the background of nonspeciﬁcally adsorbed
proteins eluted from the beads and increases the signal-to-noise.
Our initial analysis of proteins in RKO cells modiﬁed by
alkynyl or azido HNE indicated hundreds of molecular
targets.
77 These modiﬁcations were observed over a concen-
tration range of 5−50 μM alkynyl or azido HNE, and modiﬁed
proteins were detectable by SDS polyacrylamide gel elec-
trophoresis followed by Western Blotting at submicromolar
concentrations. Recent investigations suggest that the levels of
lipid electrophiles generated by activated macrophages are in
the high nM range.
79 The identities of the proteins modiﬁed in
our study revealed a broad range of targets from all major
cellular components.
77 It appears that the HNE derivatives
freely diﬀuse throughout the cell. The complexity of protein
modiﬁcation by HNE suggests that the notion of a single
molecular target explaining much of its biology is unrealistic. In
fact, it seems more likely that a diversity of cellular responses is
induced following protein modiﬁcation, and the overall
response observed represents an amalgam of parallel pathways.
Cellular Responses to Lipid Electrophile Treatment.
One way to comprehensively proﬁle cellular responses to bio-
logically active molecules is to determine changes in gene ex-
pression by microarray analysis. When we performed such
experiments with HNE, hundreds of genes were upregulated or
downregulated.
80 This was anticipated by the complexity of
protein modiﬁcation proﬁles.
77 Detailed analysis of the gene
expression changes suggested the activity of at least 14 diﬀerent
transcription factors were upregulated, and the activities of four
transcription factors were downregulated (Table 2).
81 This
appears to be an underestimate of the overall cellular response,
but it gives a good idea of the complexity involved. In order to
prioritize transcription factor signaling pathways to study in
more detail, we constructed expression vectors containing a
luciferase reporter gene downstream of some of the tran-
scription factor response elements summarized in Table 2.
Parallel transfection of these vectors into recipient cells fol-
lowed by HNE modiﬁcation indicated that the two most
dramatically aﬀected transcription factors were Nrf2, which
mediates the antioxidant response and Hsf1, which mediates
the heat-shock response.
80 Interestingly, Nrf2 was not identiﬁed
by the bioinformatics approach summarized in Table 2 indicating
the importance of utlilizing complementary biostatistical and ex-
perimental approaches to analyze complex cellular responses.
Heat-Shock Signaling as a Response to Lipid Electro-
phile Stress. The antioxidant response is a well-studied
cellular response to electrophile and oxidant treatment, but
much less work has been done on the heat-shock response, so
we focused our attention on that pathway. Validation experi-
ments conﬁrmed the induction of heat-shock genes by HNE.
The importance of heat-shock gene expression on the cellular
response to HNE was evaluated by reducing the level of the
transcription factor, Hsf1, using RNA interference.
82 Cells in
which Hsf1 was eliminated by small interfering RNA (siRNA)
treatment were much more sensitive to HNE toxicity than cells
treated with a scrambled siRNA control or cells in which the
levels of the transcription factor, Nrf2, were reduced. This not
only suggested that heat-shock signaling in response to lipid
electrophile treatment is an important adaptive response
that cells use to protect themselves from toxicity, but that
this pathway may be as important or more important than the
pathway mediated by the antioxidant response. Microarray
experiments in which gene expression changes were monitored
following HNE treatment of Hsf1-knocked-down cells identi-
ﬁed Bag3 as a critical mediator of that portion of the cellular
response dependent on heat-shock.
83
Bag3 is a member of a family of six diﬀerent genes char-
acterized initially by their ability to bind to members of the Bcl2
family of antiapoptopic proteins.
84 Our analysis indicated that
knockdown of BAG3 dramatically reduced the levels of
antiapoptopic proteins, thereby increasing the sensitivity of
the cells to HNE challenge.
83 Dramatic reductions in the levels
of Bcl2 family members were observed following lipid elec-
trophile treatment, but knockdown of Bag3 reduced their levels
even in the absence of HNE. Comparison of the sensitivity to
HNE of Hsf1 knocked-down cells indicated that the increased
sensitivity of the normal cells to Hsf1 knockdown was com-
pletely recapitulated by Bag3 knockdown. This suggested that
despite all of the complexity of the heat-shock response induced
by HNE, induction of Bag3 is a critical component. Increases in
the level of Bag3 following HNE treatment leads to the for-
mation of complexes between it, Bcl2 family members, and
Hsp70 which protects the Bcl2 family members from hydrolysis
in the proteasome (Figure 17). No impact of Bag3 levels is
observed on the levels of mRNA of the Bcl2 family members.
83
Hanahan and Weinberg have suggested that cancer cells
exhibit six hallmark molecular propertiesunlimited replicative
potential, resistance to apoptosis, self-suﬃciency in growth signals,
insensitivity to antigrowth signals, sustained angiogenesis, and the
ability to invade tissue and metastasize.
85 Recently, Elledge
proposed additional hallmarks that arise in a cancer cell because
of its rapid growth and large number of genetic mutations.
These hallmarks represent mechanisms to deal with metabolic
stress, proteotoxic stress, mitotic stress, oxidative stress, and
DNA damage stress.
86 An elevated heat-shock response is an
important contributor to resistance to proteotoxic stress.
Genetic deletion of the transcription factor, Hsf1, produces
viable mice that are highly resistant to the induction of cancer
in the two-stage mouse skin initiation−promotion model.
87
This illustrates that the ability of cancer cells to deal with
proteotoxic stress and lipid electrophile stress is an important
component of their ability to survive. Our ﬁndings linking
Hsf1 to protection of cancer cells from apoptosis mediated by
induction of Bag3 provides a direct linkage between two of the
hallmark properties of cancerthe resistance of cancer cells to
Table 2. Transcription Factors Altered in Activity by HNE
a
up-regulated activity (14)
TF enrich FDR TF enrich FDR
CREB1 3.83 × 10−6 ATF2 4.76 × 10−5
CDC5L 8.47 × 10−5 HSF1 1.65 × 10−4
HSF2 1.93 × 10−4 NFYB 2.17 × 10−4
CEBPA 0.0010 E4F1 0.0015
SREBF1 0.0023 USF1 0.0039
CEBPD 0.0047 ATF4 0.0073
ATF3 0.0084 FOXO1 0.0090
down-regulated activity (4)
TF enrich FDR TF enrich FDR
MYC 5.03 × 10−5 E2F1 0.0032
E2F3 0.0032 NRF1 0.0032
aFDR is false discovery rate, which is analogous to a p value for
statistical signiﬁcance.
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suggests that agents designed to lower Bag3 levels in cancer
cells may be useful adjuvant therapeutic agents when administered
with certain anticancer agents, especially the recently developed
agents that lower the levels of Bcl2 in cancer cells.
This analysis indicates that it is possible to use the
information provided by global proﬁling of cellular responses
to lipid electrophiles to prioritize important signaling pathways
for further experimentation. Furthermore, it suggests there is a
treasure trove of information to be mined by analysis of
individual signaling networks that may provide important new
insights into cancer etiology or its treatment. We are continuing
this analysis with several of the other transcription factors
activated or inactivated by HNE treatment.
■ MOLECULAR IMAGING OF INFLAMMATION AND
CANCER
The generation of oxidants by activated macrophages and
neutrophils is a critical factor in our defenses against infection.
However, as indicated in the introduction, there are many other
physiological components of inﬂammation that require the
generation and release of bioactive mediators. Oxidized lipids
are important constituents of the chemotactic and vasoactive
events of inﬂammation, but these mediators are products of
enzymatic transformations rather than the nonenzymatic
oxidations described above.
3 Mother Nature has co-opted the
chemistry outlined in Figure 2 to generate multiple families of
bioactive lipids. Lipoxygenases (LOX) and cyclooxygenases
(COX) catalyze controlled autoxidations of polyunsaturated
fatty acids to produce hydroperoxy fatty acids and prostaglan-
din endoperoxides, respectively.
88,89 Both types of intermedi-
ates are converted to downstream metabolitese.g., leuko-
trienes and prostaglandinsthat bind to membrane-bound
G-protein coupled receptors (Figure 18).
Cyclooxygenases in Inﬂammation and Cancer. There
are two COX enzymes (COX-1 and COX-2).
90 COX-1 and
COX-2 are approximately 60% identical in amino acid sequence
and have very similar three-dimensional structures. However,
they diﬀer substantially in their regulation, tissue localization,
and substrate speciﬁcity. COX-1 is constitutively expressed and
oxidizes only free fatty acids, whereas COX-2 is highly inducible
and oxidizes fatty acids and certain fatty acid esters and amides.
COX-2 expression is activated by a diverse array of agonists
including bacterial lipopolysaccharide. Thus, it is a major source
of prostaglandins synthesized during the inﬂammatory
response. This also makes COX-2 the molecular target for
the anti-inﬂammatory action of nonsteroidal anti-inﬂammatory
drugs (NSAIDs). Indeed, selective COX-2 inhibitors such as
rofecoxib (Vioxx) and celecoxib (Celebrex) exhibit anti-
inﬂammatory activity.
91,92
COX-2 is not expressed in most untransformed epithelial
cells, but early in transformation to malignancy it is expressed at
a high level (Figure 19).
93 In fact, the earliest premalignant
lesions that lead to most solid tumors display COX-2
expression.
94,95 As progression to malignancy occurs, COX-2
Figure 17. Relation of HNE activation of heat shock and activation of
Bag3. Reproduced with permission from ref 83. Copyright 2009.
American Society for Biochemistry and Molecular Biology.
Figure 18. LOX and COX catalysis as a source of bioactive lipids. Conversion of LOX products to resolvins and protectins is not shown.
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action contribute to the cancer progression process, and COX-
2 selective inhibitors prevent tumor development in animal
models. These discoveries were initially made in the colon, but
similar observations have been reported in most solid tumors
except ovarian cancer where COX-1 appears to be induced.
96
COX-2 inhibitors have been extensively tested in human
clinical trials for prevention and adjuvant therapy of cancer.
Studies of rofecoxib and celecoxib in colon polyp recurrence
trials demonstrated a dramatic reduction in recurrence, especially
in individuals who had large polyps removed at the beginning of
the trial.
98,99 Celecoxib exhibits dramatic eﬀects in the treat-
ment of advanced lung cancer when combined with gemcitabine
and carboplatin.
100 Stage 3 and stage 4 lung cancer patients who
express COX-2 in their tumors, demonstrated a doubling of
lifespan when celexocib was added to gemcitabine and carboplatin,
while individuals who did not express COX-2 in their lung cancers
demonstrated a poorer outcome when celecoxib was combined
with the two chemotherapeutic agents.
100 This illustrates the
importance of being able to determine whether a patient’s
cancer expresses the molecular target for a particular therapy, in
this case, COX-2. Although COX-2-selective inhibitors have
demonstrated profound cancer preventive and therapeutic
eﬀects in animal models and human clinical trials, they have
also demonstrated cardiovascular side eﬀects that have limited
their use for prevention and therapy. This is especially true for
patients who would be on the drug for a period of years. Thus,
COX-2 is a highly validated target for cancer prevention and
treatment but one where careful analysis of the risk/beneﬁt
ratio is absolutely necessary before beginning therapy.
101
Imaging COX-2. The established value of COX-2 as a
cancer therapeutic target combined with the need to carefully
select appropriate patients led us to hypothesize that it might
be an attractive target for molecular imaging. Early detection
remains the best way to reduce mortality from cancer, so we felt
that imaging COX-2 might be an eﬀective way to impact the
disease. The structure of both COX proteins makes them
nearly ideal targets for imaging (Figure 20).
102−104 The active
site where substrates and inhibitors bind is located deep in the
interior of the protein and is connected to the exterior through
a long channel. A gate separates the active site from the rest of
the channel, and this gate is typically closed once an inhibitor or
substrate binds.
Our laboratory described several years ago that amides and
esters of certain carboxylic acid-containing NSAIDs exhibit
COX-2 selectivity.
105 This provided the basis for our design
strategy for the construction of COX-2-targeted imaging agents.
An NSAID core is tethered to a ﬂuorophore to generate an
optical imaging agent that will accumulate in COX-2 expressing
cells and tissue. To test our strategy, we evaluated a number of
Figure 19. COX-2 is expressed at the earliest detected premalignant phase of colon cancer. Reproduced with permission from ref 97. 1999. Nature
Publishing Group.
Figure 20. Stereodrawing of the COX-2 active site. Reproduced from ref 89. 2003. American Chemical Society.
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phores. Each compound was evaluated for COX-2 selectivity
against puriﬁed COX-1 and COX-2, for potency in intact cells,
and for the ability to image COX-2 in intact cells. Candidates
that survived this gauntlet were then evaluated in mouse
models of inﬂammation and cancer for their ability to accu-
mulate in tissues expressing high levels of COX-2. Some 250
compounds were made and evaluated; most of them did not
inhibit COX-2 or they did not penetrate the cell membrane.
However, two compounds were quite eﬀective in both in vitro
and in vivo experiments.
106 These compounds contained indo-
methacin as the NSAID core tethered through a butylenediamine
linker to the ﬂuorophore carboxy-X-rhodamine (Figure 21).
Although these compounds were promising, purchase of
the ﬂuorophore from commercial vendors is extraordinarily
expensive which limits their utility for in vivo experiments.
Therefore, we developed a straightforward synthetic route to
the two carboxy-X-rhodamine isomers that enables inexpensive
preparation of both compounds (Figure 22).
107
The target compounds were evaluated in multiple in vivo
models.
106 Since COX-2 is an important inducible component
of the inﬂammatory response, the utility of the COX-2-targeted
imaging agents (termed ﬂuorocoxibs) was examined in the
mouse footpad model of inﬂammation. Injection of carrageenan
into one footpad of a mouse induces a profound inﬂammatory
response, which is accompanied by the induction of high levels
of COX-2 within approximately 12 h. Twenty-four hours after
carrageenan injection, ﬂuorocoxib A was injected into the
peritoneal cavity of the treated mouse, and optical imaging
performed 3−5 h thereafter. As Figure 23 illustrates, com-
pounds selectively accumulated in the inﬂamed paw, but not in
the noninﬂamed contralateral paw.
Indeed, this is one of the attractive features of the footpad
model of inﬂammation; every animal serves as its own control.
Parallel experiments using animals in which COX-2 had been
genetically deleted (i.e., COX-2 knockouts) revealed no selec-
tive accumulation in the inﬂamed compared to the noninﬂamed
paw, indicating that the uptake in the wild-type animals was
dependent upon the presence of COX-2 in the tissue. This was
conﬁrmed by pretreating wild-type animals with either the
nonselective NSAID, indomethacin, or the selective COX-2
inhibitor, celecoxib, prior to ﬂuorocoxib administration. Either
inhibitor prevented accumulation of ﬂuorocoxib in the inﬂamed
lesion. A particularly useful control compound is an analog of
ﬂuorocoxib B in which the four-carbon tether is shortened to
two carbons. Because of the shortened tether, this compound is
unable to inhibit COX-2. It contains the same indomethacin
core and the same carboxy-X-rhodamine ﬂuorophore but it is
not a COX-2 inhibitor, so it is a very useful negative control for
in vivo experiments. Comparison of the uptake of ﬂuorocoxib B
and the negative control molecule (Figure 24) illustrates that
no accumulation in the inﬂamed lesion is observed following
injection of the compound that is unable to bind to COX-2.
Thus, genetic and pharmacological experiments validate the
hypothesis that ﬂuorocoxib A and B accumulate in inﬂamed
tissue because of the presence of COX-2 in that tissue.
Figure 21. Fluorocoxibs A and B.
Figure 22. Synthetic route to the carboxy-X-rhodamine precursors of
ﬂuorocoxibs. Reproduced from ref 107. 2008. American Chemical
Society.
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xenografts in nude mice.
106 Figure 25 shows the comparison of
uptake into a COX-2-expressing human head and neck cancer
(1483) or non-COX-2-expressing human colon cancer
(HCT116) grown on the ﬂanks of a nude mouse. Compounds
were injected retro-orbitally, and the residue can be seen at the
site of injection. Three-and-one-half hours after administration
of ﬂuorocoxib A, ﬂuorescence was observed in human tumors
that express COX-2 but not in tumors that do not express
COX-2. Furthermore, pretreatment of these animals with either
indomethacin or celecoxib abolishes uptake of the ﬂuorocoxib
into the COX-2-expressing tumor. The identity of the ﬂuo-
rescent material in the tumor xenografts was established by
extraction of the tumor and analysis by liquid chromatography
and mass spectrometry. A single ﬂuorescent peak was observed
that coelutes with ﬂuorocoxib A and displays an identical mass
spectrum. Thus, the ﬂuorescent material that accumulates in
the human tumor expressing COX-2 is the parent molecule,
ﬂuorocoxib A. Pharmacokinetic analysis of the disposition of
this molecule in nude mice bearing tumors illustrates rapid
uptake and distribution into plasma, liver, and kidney but not
into the tumor. Accumulation in the tumor requires 3−5h
postinjection to achieve maximal uptake. However, whereas
elimination of ﬂuorocoxib A from plasma, liver, and kidney is
rapid, elimination from the tumor is not. Thus, ﬂuorescence can
be detected in the tumor 24 h after administration. LC/MS
analysis veriﬁes that this material is the parent compound,
ﬂuorocoxib A.
The ﬁnal in vivo model in which use of these compounds was
validated was the APCMin+ (Min) mouse model of intestinal
tumorigenesis.
106 The Min mouse bears a mutation in the same
APC gene that is mutated in individuals born with familial
polyposis. In humans, this leads to a large number of colon
tumors by midteens and ultimately the development of colon
cancer. In mice, the mutation results in small intestinal tumors.
Three hours following retro-orbital administration of ﬂuo-
rocoxib A to a Min mouse, uptake of ﬂuorophore into these
small intestinal tumors is detectable (Figure 26). Comparison
of light emission from the tumors to light emission from
surrounding normal tissue indicates a 50- to 100-fold uptake
selectivity. This is the highest selectivity of accumulation of
a targeted ﬂuorophore into a tumor that has been reported
to date.
Figure 23. Accumulation of ﬂuorocoxibs in the inﬂamed paw.
Carageenan was injected into the paw at time zero. After 24 h, the
ﬂuorocoxib was administered by intraperitoneal injection.
Figure 24. Comparison of ﬂuorocoxib B uptake with that of LM4752.
T h es a m ep r o t o c o lw a sf o l l o w ed as described in Figure 23.
Reproduced with permission from ref 106. 2010. American Association
for Cancer Research.
Figure 25. Xenograft data on uptake of ﬂuorocoxib A. Fluorocoxib A
was administered by retro-orbital injection and the animals monitored
for ﬂuorescence 3.5 h later using a Xenogen camera. The head-and-
neck cancer, 1483, expresses COX-2 whereas the colon cancer,
HCT116, does not express COX-2. Reproduced with permission from
ref 106. 2010. American Association for Cancer Research.
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design and synthesize a COX-2-targeted optical imaging agent
that is useful in vivo. The attrition rate of candidate compounds
was extremely high (>98%), but this is not surprising when one
considers that a successful imaging agent must selectively
inhibit COX-2, have stability and pharmacokinetics suitable
for delivery to and uptake by the tumor, be able to traverse
the cell membrane to reach the enzyme in the endoplasmic
reticulum and nuclear membrane, and have ﬂuorescent
properties suitable for detection with minimal autoﬂuo-
rescence interference.
In addition to optical imaging agents, our laboratory has
reported the synthesis and in vivo validation of radiologic
imaging agents for both SPECT and PET imaging.
108,109 The
structures of the agents are diﬀerent from those of the optical
imaging agents and are based on the celecoxib and rofecoxib
scaﬀolds containing either 123Io r18F (Figure 27). The validation
process for both compounds closely followed that described
above for the ﬂuorocoxibs. Thus, we have prepared an
inventory of COX-2-targeted agents for in vivo imaging that
includes representatives of several of the currently available
modalities for in vivo detection.
■ FUTURE OPPORTUNITIES
Chemical studies of DNA and protein damage by reactive
species generated during the inﬂammatory response are being
aggressively pursued in a number of laboratories. Adducts are
being identiﬁed and the biological consequences of their
formation explored. There is great interest in developing
biomarkers of this type of damage and applying them in
population-based studies to relate chemical modiﬁcation to
disease susceptibility. Whether direct products of chemical
modiﬁcation or biomolecules synthesized during the tissue
response to damage will be most useful as biomarkers is
uncertain.
Mechanistic investigation of the cellular responses to reactive
oxidants and electrophiles is in its infancy. The complexity of
the cellular response to a single electrophile revealed by the
data in Table 2 suggests it will be a daunting task to establish
cause-and-eﬀect relationships between chemical modiﬁcation of
protein or DNA and the induction of a particular cellular
response. Nevertheless, the importance of stress responses in
cancer cell survival suggests there may be a payoﬀ to studying
these relationships. Based on the studies summarized above,
eﬀorts are underway to test the potential of BAG3 as a
druggable target for cancer therapy.
Molecular imaging agents are anticipated to have a major
eﬀect on the detection and treatment of cancer. COX-2-
targeted imaging agents represent only one class of what is
already a treasure trove of targeted optical or radiological
imaging agents. Fluorocoxib A and B are now commercially
available for preclinical experiments and are being advanced
for human clinical trials. The type of applications that one
can envisage include early detection of premalignancy or
malignancy, detection of tumor margins during surgery,
stratiﬁcation of patients for the presence of COX-2 prior
to therapy, or monitoring response to therapy. A number
of tissues are attractive for the use of such compounds
including skin, esophagus, stomach, colon, and bladder
because technology is available to deliver and collect light in
these locations.
If a large bulky ﬂuorophore, such as carboxy-X-rhodamine,
can be selectively delivered to a human tumor expressing COX-
2, the question to be answered in the future is whether we can
also selectively deliver chemotherapy. This approach would be
anticipated to increase the concentration of the chemo-
therapeutic agent in the tumor relative to normal tissue,
thereby improving the therapeutic index. Development of
targeted chemotherapeutic agents would face all of the same
hurdles as optical imaging agents with the additional require-
ment that the chemotherapeutic moiety be active once it
reaches the target tissue. This adds the complexity of
incorporating the ability to release the active chemotherapeutic
agent at the site of accumulation if the COX-2 targeted
conjugate is not directly active. We are aggressively pursuing
these challenges and opportunities.
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